BUFFALO, N.Y., April 23, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that its board of directors has appointed Julia Brown and Anthony Principi as new independent directors and David Hohn, M.D., a current director, as Chairman of the board. Bernard Kasten, M.D. and Michael Fonstein, Ph.D., will retire from the board at the Company's 2013 annual meeting of shareholders, following the expiration of their current terms. David Hohn, M.D., Chairman of the board, commented, "We are very excited to have Julia and Tony on our team. Julia is a 40-year biotechnology industry professional, who has served in senior executive positions at development and commercial stage companies, including a 25 year tenure at Eli Lilly and Company. She brings specialized expertise in commercial operations, business and corporate development, partnering, strategic planning and corporate governance. Tony is a highly decorated war veteran who has served in numerous senior administration roles in the U.S. Government and as a senior executive at Pfizer, Inc. I am confident that Julia and Tony's complementary experience and ability to provide strategic guidance at all levels will add great value to our board. CBLI has been making a major transformation over the past year and I am excited about working closely with our executive management team and the board in my role as Chairman to move the organization forward." "We are thrilled to gain the specialized industry know-how and counsel of Julia and Tony as CBLI continues to develop into a more clinically-oriented oncology company with a pivotal-stage radiation countermeasure," stated Yakov Kogan, Ph.D., MBA, Chief Executive Officer and board member. "Over the last year, we intensified our focus on regulatory affairs and clinical development, which is reflected by our operational leadership. Now we are proud to take the first steps in more closely aligning the representation on our board with this strategic direction. Julia and Tony's understanding of the biotechnology and pharmaceutical industries, as well as the challenges of managing growth and working with government agencies will be invaluable as we advance our oncology clinical trials and pursue approval of Entolimod™ as a radiation countermeasure."